![](https://endpts.com/wp-content/uploads/2022/03/Andrew-Obenshain-bluebird-bio-tile-scaled.jpg)
Andrew Obenshain, bluebird bio CEO
Bluebird bio starts 15 patients on its three multimillion-dollar gene therapies
Bluebird bio’s stock $BLUE jumped over 20% on Thursday following its first-quarter earnings release and the announcement of 15 patients starting on its three approved …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.